| Bioactivity | Umirolimus, a macrocyclic triene lactone Rapamycin derivative, is powerful immunosuppressant and anti-inflammatory agent. Umirolimus has highly lipophilicity and can be used drug-eluting stent (DES) applications[1]. | ||||||||||||
| Invitro | Umirolimus is a macrocyclic triene lactone, developed with pharmacological properties specifically tailored for localized drug delivery. Umirolimus can be used drug-eluting stent (DES) applications. Owing to its enhanced lipophilicity,it is strongly attracted to binding sites within the vessel wall and small, tortuous vessels, and contributing to cellular absorption and sustained distribution in the vessel wall surrounding the stent[1]. Umirolimus prevents progression of the cell cycle in G1 phase by inhibiting IL-2/mTOR-mediated P70-KD S6 protein kinase activation. Umirolimus inhibits T-cell growth, as well as smooth muscle cell growth[1]. | ||||||||||||
| In Vivo | The elimination half-life of Umirolimus is approximately 25 h in whole blood[1]. | ||||||||||||
| Name | Umirolimus | ||||||||||||
| CAS | 851536-75-9 | ||||||||||||
| Formula | C55H87NO14 | ||||||||||||
| Molar Mass | 986.28 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Eberhard Grube, et al. BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease. Expert Rev Med Devices. 2006 Nov;3(6):731-41. |
Umirolimus
CAS: 851536-75-9 F: C55H87NO14 W: 986.28
Umirolimus, a macrocyclic triene lactone Rapamycin derivative, is powerful immunosuppressant and anti-inflammatory agent
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.